{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for l root_references_url in Reference URL (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT02710747: Phase 4 Interventional Unknown status Heart Valve Disease
(2015)
Source URL:
Class:
PROTEIN
Status:
Excipient
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Vivant True Tone Forte by Vivant Pharmaceuticals, LLC
(2024)
Source URL:
First approved in 2024
Source:
Vivant True Tone Forte by Vivant Pharmaceuticals, LLC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Acclean Anti-Cavity by Henry Schein, Inc.
(2025)
Source URL:
First approved in 2011
Source:
21 CFR 355
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA205987
(2009)
Source URL:
First approved in 2009
Source:
ANDA205987
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA209654
(2003)
Source URL:
First approved in 2003
Source:
ANDA209654
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA091079
(2002)
Source URL:
First approved in 2002
Source:
ANDA091079
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA091079
(2002)
Source URL:
First approved in 2002
Source:
ANDA091079
Source URL:
Class:
POLYMER
